6 results on '"Ongaro, Marco"'
Search Results
2. Immuno-Transcriptomic Profiling of Blood and Tumor Tissue Identifies Gene Signatures Associated with Immunotherapy Response in Metastatic Bladder Cancer
- Author
-
Desponds, Emma, primary, Croci, Davide, additional, Wosika, Victoria, additional, Hadadi, Noushin, additional, Fonseca Costa, Sara S., additional, Ciarloni, Laura, additional, Ongaro, Marco, additional, Zdimerova, Hana, additional, Leblond, Marine M., additional, Hosseinian Ehrensberger, Sahar, additional, Romero, Pedro, additional, and Verdeil, Grégory, additional
- Published
- 2024
- Full Text
- View/download PDF
3. Development of Traceable Mouse Models of Advanced and Metastatic Bladder Cancer.
- Author
-
Desponds, Emma, Kioseoglou, Konstantina, Zdimerova, Hana, Ongaro, Marco, Verdeil, Grégory, and Leblond, Marine M.
- Subjects
BLADDER tumors ,BIOLOGICAL models ,TRANSGENIC animals ,RESEARCH funding ,IMMUNOTHERAPY ,ANIMALS ,IN vivo studies ,MANN Whitney U Test ,METASTASIS ,GENE expression ,MICE ,IMMUNOHISTOCHEMISTRY ,CELL lines ,IMMUNE checkpoint inhibitors ,ANIMAL experimentation ,ONE-way analysis of variance ,GENETIC mutation ,TUMOR antigens ,DISEASE progression - Abstract
Simple Summary: Poor prognosis for advanced bladder cancer underlines the need for a better understanding of tumor resistance to treatment in relevant preclinical models. We developed new models of inducible and orthotopic muscle-invasive bladder cancer, with strong phenotypical and genetic resemblances to the human disease. These models enable real-time tracking of tumor progression and metastasis through bioluminescence imaging to facilitates the testing of new therapies. This valuable tool is important for advancing bladder cancer research and developing more effective treatments. Bladder cancer (BC) is the fourth most common cancer in men, with a poor patient prognosis for advanced disease. The poor survival of patients with muscle-invasive bladder cancer (MIBC) and metastatic status emphasizes the urgent need to develop new therapies. Lacking in the field of BC is the availability of relevant advanced BC mouse models, especially metastatic ones, that accurately recapitulate the complexities of human pathology to test and study new therapeutic strategies. Addressing this need, we developed a traceable mouse model of BC that expresses tumor-associated antigens within the context of advanced muscle-invasive BC. This novel system was achieved through the deletion of the tp53 and pten genes, alongside the incorporation of the fusion construct of Firefly luciferase (Luc) and the SIYRYYGL (SIY) T-cell antigen. We validate that the presence of the transgene did not impact on the development of the tumors while allowing us to measure tumor progression by bioluminescence. We show that the transgene did not influence the composition of the immune tumor microenvironment. More importantly, we report that this model was unresponsive to anti-PD-1 treatment, as in the majority of patients with BC. We also develop a new model based on the orthotopic injection of BC clonal cell lines derived from our first model. We demonstrate that this new model invades the muscle layer and has a metastasis development rate of 83%. The advantage of this model is that we can visualize tumor growth and metastasis development in vivo. These mouse models' characteristics, displaying many similarities with the human pathology, provide a valuable tool for tracking tumor progression, metastasis spread in vivo, and treatment resistance, as well as exploring fundamental and translational aspects of BC biology. This work contributes to the improvement in the landscape of mouse models of advanced BC for testing new therapeutic strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. PGE2 inhibits TIL expansion by disrupting IL-2 signalling and mitochondrial function.
- Author
-
Morotti, Matteo, Grimm, Alizee J., Hope, Helen Carrasco, Arnaud, Marion, Desbuisson, Mathieu, Rayroux, Nicolas, Barras, David, Masid, Maria, Murgues, Baptiste, Chap, Bovannak S., Ongaro, Marco, Rota, Ioanna A., Ronet, Catherine, Minasyan, Aspram, Chiffelle, Johanna, Lacher, Sebastian B., Bobisse, Sara, Murgues, Clément, Ghisoni, Eleonora, and Ouchen, Khaoula
- Abstract
Expansion of antigen-experienced CD8
+ T cells is critical for the success of tumour-infiltrating lymphocyte (TIL)-adoptive cell therapy (ACT) in patients with cancer1. Interleukin-2 (IL-2) acts as a key regulator of CD8+ cytotoxic T lymphocyte functions by promoting expansion and cytotoxic capability2,3. Therefore, it is essential to comprehend mechanistic barriers to IL-2 sensing in the tumour microenvironment to implement strategies to reinvigorate IL-2 responsiveness and T cell antitumour responses. Here we report that prostaglandin E2 (PGE2 ), a known negative regulator of immune response in the tumour microenvironment4,5, is present at high concentrations in tumour tissue from patients and leads to impaired IL-2 sensing in human CD8+ TILs via the PGE2 receptors EP2 and EP4. Mechanistically, PGE2 inhibits IL-2 sensing in TILs by downregulating the IL-2Rγc chain, resulting in defective assembly of IL-2Rβ–IL2Rγc membrane dimers. This results in impaired IL-2–mTOR adaptation and PGC1α transcriptional repression, causing oxidative stress and ferroptotic cell death in tumour-reactive TILs. Inhibition of PGE2 signalling to EP2 and EP4 during TIL expansion for ACT resulted in increased IL-2 sensing, leading to enhanced proliferation of tumour-reactive TILs and enhanced tumour control once the cells were transferred in vivo. Our study reveals fundamental features that underlie impairment of human TILs mediated by PGE2 in the tumour microenvironment. These findings have therapeutic implications for cancer immunotherapy and cell therapy, and enable the development of targeted strategies to enhance IL-2 sensing and amplify the IL-2 response in TILs, thereby promoting the expansion of effector T cells with enhanced therapeutic potential.Prostaglandin E2 from the tumour microenvironment impairs interleukin-2 sensing by tumour-infiltrating lymphocytes, restricting proliferative response and promoting T cell death via metabolic impairment and ferroptosis. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
5. Biological acidification of “Vino Santo di Gambellara” by mixed fermentation of L. thermotolerans and S. cerevisiae. Role of nitrogen in the evolution of fermentation and aroma profile
- Author
-
Gallo, Adelaide, primary, Guzzon, Raffaele, additional, Paolini, Mauro, additional, Malacarne, Mario, additional, Ongaro, Marco, additional, and Roman, Tomas, additional
- Published
- 2023
- Full Text
- View/download PDF
6. PGE2inhibits TIL expansion by disrupting IL-2 signalling and mitochondrial function
- Author
-
Morotti, Matteo, Grimm, Alizee J., Hope, Helen Carrasco, Arnaud, Marion, Desbuisson, Mathieu, Rayroux, Nicolas, Barras, David, Masid, Maria, Murgues, Baptiste, Chap, Bovannak S., Ongaro, Marco, Rota, Ioanna A., Ronet, Catherine, Minasyan, Aspram, Chiffelle, Johanna, Lacher, Sebastian B., Bobisse, Sara, Murgues, Clément, Ghisoni, Eleonora, Ouchen, Khaoula, Bou Mjahed, Ribal, Benedetti, Fabrizio, Abdellaoui, Naoill, Turrini, Riccardo, Gannon, Philippe O., Zaman, Khalil, Mathevet, Patrice, Lelievre, Loic, Crespo, Isaac, Conrad, Marcus, Verdeil, Gregory, Kandalaft, Lana E., Dagher, Julien, Corria-Osorio, Jesus, Doucey, Marie-Agnes, Ho, Ping-Chih, Harari, Alexandre, Vannini, Nicola, Böttcher, Jan P., Dangaj Laniti, Denarda, and Coukos, George
- Abstract
Expansion of antigen-experienced CD8+T cells is critical for the success of tumour-infiltrating lymphocyte (TIL)-adoptive cell therapy (ACT) in patients with cancer1. Interleukin-2 (IL-2) acts as a key regulator of CD8+cytotoxic T lymphocyte functions by promoting expansion and cytotoxic capability2,3. Therefore, it is essential to comprehend mechanistic barriers to IL-2 sensing in the tumour microenvironment to implement strategies to reinvigorate IL-2 responsiveness and T cell antitumour responses. Here we report that prostaglandin E2 (PGE2), a known negative regulator of immune response in the tumour microenvironment4,5, is present at high concentrations in tumour tissue from patients and leads to impaired IL-2 sensing in human CD8+TILs via the PGE2receptors EP2 and EP4. Mechanistically, PGE2inhibits IL-2 sensing in TILs by downregulating the IL-2Rγcchain, resulting in defective assembly of IL-2Rβ–IL2Rγcmembrane dimers. This results in impaired IL-2–mTOR adaptation and PGC1α transcriptional repression, causing oxidative stress and ferroptotic cell death in tumour-reactive TILs. Inhibition of PGE2signalling to EP2 and EP4 during TIL expansion for ACT resulted in increased IL-2 sensing, leading to enhanced proliferation of tumour-reactive TILs and enhanced tumour control once the cells were transferred in vivo. Our study reveals fundamental features that underlie impairment of human TILs mediated by PGE2in the tumour microenvironment. These findings have therapeutic implications for cancer immunotherapy and cell therapy, and enable the development of targeted strategies to enhance IL-2 sensing and amplify the IL-2 response in TILs, thereby promoting the expansion of effector T cells with enhanced therapeutic potential.
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.